Chemistry:Sitneprotafib

From HandWiki

Sitneprotafib (JAB-3312) is a drug that acts as an inhibitor of the protein tyrosine phosphatase enzyme SHP-2 (PTPN11). It has been researched for the treatment of cancer and is in clinical trials as a combination treatment with glecirasib.[1][2][3]

References

  1. ↑ "Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312". Cancer Research Communications 5 (5): 792–803. May 2025. doi:10.1158/2767-9764.CRC-25-0001. PMID 40304209. 
  2. ↑ "JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies". Clinical Cancer Research 31 (14): 3019–3032. July 2025. doi:10.1158/1078-0432.CCR-24-3691. PMID 40333694. 
  3. ↑ "Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial". The Lancet. Respiratory Medicine. November 2025. doi:10.1016/S2213-2600(25)00258-9. PMID 41325755. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Sitneprotafib&oldid=4245218"